$HALB Why Halberd Corporation Selected ASU And Whe
Post# of 102241
(Total Views: 160)
Posted On: 09/02/2020 8:11:17 AM
$HALB Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities
Halberd Corporation (OTC PINK:HALB) today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment.
ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services funding among all U.S. institutions without a medical school, placing them ahead of Princeton, Georgia Tech and Carnegie Mellon University. Moreover, U.S. News and World Report named ASU as the most innovative university each year from 2016 -2020, ranking it ahead of such notable institutions as Stanford and MIT.
William A. Hartman, Halberd's Chairman, President & CEO stated, "Before engaging ASU, we reviewed six major universities in the United States. After evaluating all pertinent factors necessary for an institutional research partner, we determined that ASU met all of our criteria. ASU is a highly rated university in research and innovation, and we are fortunate to have them working with us on our project to develop a curative treatment for Covid-19. The efforts will also extend to treatments for other blood-borne and neurologic diseases using our patented extracorporeal treatment process. Halberd seeks a robust treatment beyond coronavirus yielding a pandemic-free society."
Halberd Corporation (OTC PINK:HALB) today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment.
ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services funding among all U.S. institutions without a medical school, placing them ahead of Princeton, Georgia Tech and Carnegie Mellon University. Moreover, U.S. News and World Report named ASU as the most innovative university each year from 2016 -2020, ranking it ahead of such notable institutions as Stanford and MIT.
William A. Hartman, Halberd's Chairman, President & CEO stated, "Before engaging ASU, we reviewed six major universities in the United States. After evaluating all pertinent factors necessary for an institutional research partner, we determined that ASU met all of our criteria. ASU is a highly rated university in research and innovation, and we are fortunate to have them working with us on our project to develop a curative treatment for Covid-19. The efforts will also extend to treatments for other blood-borne and neurologic diseases using our patented extracorporeal treatment process. Halberd seeks a robust treatment beyond coronavirus yielding a pandemic-free society."
(0)
(0)Scroll down for more posts ▼